Table_5_Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19.XLSX
Human leukocyte antigen (HLA) class I molecules play a crucial role in the development of a specific immune response to viral infections by presenting viral peptides at the cell surface where they will be further recognized by T cells. In the present manuscript, we explored whether HLA class I genotypes can be associated with the critical course of Coronavirus Disease-19 by searching possible connections between genotypes of deceased patients and their age at death. HLA-A, HLA-B, and HLA-C genotypes of n = 111 deceased patients with COVID-19 (Moscow, Russia) and n = 428 volunteers were identified with next-generation sequencing. Deceased patients were split into two groups according to age at the time of death: n = 26 adult patients aged below 60 and n = 85 elderly patients over 60. With the use of HLA class I genotypes, we developed a risk score (RS) which was associated with the ability to present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides by the HLA class I molecule set of an individual. The resulting RS was significantly higher in the group of deceased adults compared to elderly adults [p = 0.00348, area under the receiver operating characteristic curve (AUC ROC = 0.68)]. In particular, presence of HLA-A*01:01 allele was associated with high risk, while HLA-A*02:01 and HLA-A*03:01 mainly contributed to low risk. The analysis of patients with homozygosity strongly highlighted these results: homozygosity by HLA-A*01:01 accompanied early deaths, while only one HLA-A*02:01 homozygote died before 60 years of age. Application of the constructed RS model to an independent Spanish patients cohort (n = 45) revealed that the score was also associated with the severity of the disease. The obtained results suggest the important role of HLA class I peptide presentation in the development of a specific immune response to COVID-19.
History
References
- https://doi.org//10.1128/JVI.78.11.5535-5545.2004
- https://doi.org//10.1111/all.14647
- https://doi.org//10.1111/all.14523
- https://doi.org//10.1186/1743-422X-6-46
- https://doi.org//10.3389/fimmu.2016.00013
- https://doi.org//10.1073/pnas.93.21.11786
- https://doi.org//10.1038/nri2357
- https://doi.org//10.1086/421523
- https://doi.org//10.1186/1471-2350-4-9
- https://doi.org//10.1128/JCM.44.2.359-365.2006
- https://doi.org//10.1089/vim.2011.0024
- https://doi.org//10.1016/j.clim.2020.108572
- https://doi.org//10.1186/s12967-020-02515-5
- https://doi.org//10.1093/nar/gkz950
- https://doi.org//10.1002/gch2.1018
- https://doi.org//10.1002/pro.3290
- https://doi.org//10.1128/JVI.00510-20
- https://doi.org//10.1007/s00251-005-0781-7
- https://doi.org//10.1093/nar/gkaa379
- https://doi.org//10.1038/s41592-019-0686-2
- https://doi.org//10.1109/MCSE.2007.55
- https://doi.org//10.18087/cardio.2019.6.2595
- https://doi.org//10.1016/j.diabres.2016.02.010
- https://doi.org//10.1080/20479700.2020.1801164
- https://doi.org//10.1002/jmv.26147
- https://doi.org//10.1164/rccm.202003-0543OC
- https://doi.org//10.1513/AnnalsATS.202003-225OC
- https://doi.org//10.1136/bmj.m1091
- https://doi.org//10.3897/popecon.3.e47234
- https://doi.org//10.1016/S2213-2600(20)30079-5
- https://doi.org//10.18632/aging.103000
- https://doi.org//10.1038/s41569-018-0119-4
- https://doi.org//10.1016/j.tips.2020.06.001
- https://doi.org//10.1111/tan.13941
- https://doi.org//10.1126/science.283.5408.1748
- https://doi.org//10.1101/2020.10.27.20220863
- https://doi.org//10.1016/j.chom.2020.03.002
- https://doi.org//10.1016/j.cell.2020.05.015
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity